Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Repository of the University of Ljubljana
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Advanced
New in RUL
About RUL
In numbers
Help
Sign in
Details
The genetic blueprint of obesity : from pathogenesis to novel therapies
ID
Tonin, Gašper
(
Author
),
ID
Eržen, Stjepan
(
Author
),
ID
Mlinarič, Zala
(
Author
),
ID
Jurišić-Eržen, Dubravka
(
Author
),
ID
Horvat, Simon
(
Author
),
ID
Kunej, Tanja
(
Author
),
ID
Klen, Jasna
(
Author
)
PDF - Presentation file,
Download
(6,56 MB)
MD5: 39469F178919DD63FE88A666F2112015
URL - Source URL, Visit
https://onlinelibrary.wiley.com/doi/10.1111/obr.13978
Image galllery
Abstract
Obesity is a chronic metabolic disease characterized by disturbances in energy homeostasis, leading to excessive fat accumulation. The pathogenesis of the disease is shaped by a complex interplay of genetic, epigenetic, biological, psychological, and environmental factors. These contributors affect regulatory mechanisms in the hypothalamus, hormonal signaling, and the gut-brain axis, all of which control energy intake, expenditure, and energy utilization in body tissues. In this context, particular attention is given to the role of genetic factors, which have a major impact on an individual's susceptibility to disease and support the development of personalized preventive and therapeutic approaches. Modern obesity treatment goes beyond weight reduction and focuses on optimizing body composition by reducing fat mass and increasing lean mass. This review includes a detailed overview of the mechanisms and clinical effects of current pharmacological approaches to obesity treatment, alongside other established strategies such as lifestyle modifications and bariatric surgery. It specifically discusses lipase inhibitors, opioid antagonists, sympathomimetics, and GLP-1 receptor agonists. Looking ahead, emerging therapies—such as microbiota modulation, dual and triple drug combinations, PYY agonists, and monoclonal antibodies—are expected to play a crucial role in the management of obesity. Furthermore, this review explores the potential of CRISPR-based technology for monogenic obesity, opening new avenues for targeted obesity treatments and identifying promising research directions. In the time to come, personalized medicine might have a fundamental place in the management of obesity, providing tailored and more effective therapeutic approaches that prioritize the long-term improvement of body composition and health outcomes in patients.
Language:
English
Keywords:
CRISPR/Cas9
,
dual therapy
,
energy homeostasis
,
gene therapy
,
gut–brain axis
,
microbiota
,
personalized medicine
Work type:
Article
Typology:
1.02 - Review Article
Organization:
MF - Faculty of Medicine
BF - Biotechnical Faculty
Publication status:
Published
Publication version:
Version of Record
Year:
2025
Number of pages:
38 str.
Numbering:
Vol. 26, iss. 12, art. e13978
PID:
20.500.12556/RUL-176190
UDC:
575
ISSN on article:
1467-789X
DOI:
10.1111/obr.13978
COBISS.SI-ID:
242378243
Publication date in RUL:
24.11.2025
Views:
112
Downloads:
26
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Record is a part of a journal
Title:
Obesity reviews
Shortened title:
Obes. rev.
Publisher:
Wiley, World Obesity Federation
ISSN:
1467-789X
COBISS.SI-ID:
517799449
Licences
License:
CC BY-NC-ND 4.0, Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Link:
http://creativecommons.org/licenses/by-nc-nd/4.0/
Description:
The most restrictive Creative Commons license. This only allows people to download and share the work for no commercial gain and for no other purposes.
Secondary language
Language:
Slovenian
Keywords:
genetika
,
debelost
,
patogeneza
,
terapije
Projects
Funder:
ARIS - Slovenian Research and Innovation Agency
Project number:
P4-0220
Name:
Primerjalna genomika in genomska biodiverziteta
Funder:
ARIS - Slovenian Research and Innovation Agency
Project number:
J7-60131
Name:
Integracija epigenomike in prostorske transkriptomike pri poligenem živalskem modelu za debelost
Similar documents
Similar works from RUL:
Similar works from other Slovenian collections:
Back